JETRO Opens Japan Entry Acceleration Program 2026 for Regenerative Medicine Companies
JETRO has opened applications for JEAP 2026, a Japan-entry acceleration program for overseas regenerative-medicine companies seeking Japanese partners.
Insights
JETRO has opened applications for JEAP 2026, a Japan-entry acceleration program for overseas regenerative-medicine companies seeking Japanese partners.
Japan is open to foreign companies, capital, and technology. But in a high-risk world, Japan is not only asking what you sell. It is asking whether you can be trusted as a partner.
Japan is still open to foreign companies, but entry is becoming more selective. The companies that prepare for partnerships, not just promotion, will have a stronger chance.